Ani pharmaceuticals announces fda approval and imminent launch of rifabutin capsules usp

Baudette, minn.--(business wire)--ani pharmaceuticals, inc. (“ani” or the “company”) (nasdaq: anip) today announced that the company received u.s. food and drug administration (“fda”) approval for the abbreviated new drug application for rifabutin capsules usp, 150 mg. ani's rifabutin capsules are the generic version of the reference listed drug mycobutin®. the current annual u.s. market for rifabutin capsules usp, 150 mg is approximately $16.6 million, according to iqvia/ims health, a leading
ANIP Ratings Summary
ANIP Quant Ranking